Gee M, Han A, Lofgren S, Beausang J, Mendoza J, Birnbaum M, et al. Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes. Cell. 2018;172:549-563.e16 pubmed publisher

Lederer K, Bettini E, Parvathaneni K, Painter M, Agarwal D, Lundgreen K, et al. Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. Cell. 2022;185:1008-1024.e15 pubmed publisher

Bergamaschi L, Mescia F, Turner L, Hanson A, Kotagiri P, Dunmore B, et al. Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity. 2021;54:1257-1275.e8 pubmed publisher

Pan Y, Aiamkitsumrit B, Bartolo L, Wang Y, Lavery C, Marc A, et al. Vaccination reshapes the virus-specific T cell repertoire in unexposed adults. Immunity. 2021;54:1245-1256.e5 pubmed publisher

Nielsen C, Ogbe A, Pedroza Pacheco I, Doeleman S, Chen Y, Silk S, et al. Protein/AS01B vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors. Cell Rep Med. 2021;2:100207 pubmed publisher

Sutton H, Aye R, Idris A, Vistein R, Nduati E, Kai O, et al. Atypical B cells are part of an alternative lineage of B cells that participates in responses to vaccination and infection in humans. Cell Rep. 2021;34:108684 pubmed publisher

Dijkman K, Aguilo N, Boot C, Hofman S, Sombroek C, Vervenne R, et al. Pulmonary MTBVAC vaccination induces immune signatures previously correlated with prevention of tuberculosis infection. Cell Rep Med. 2021;2:100187 pubmed publisher

Stathopoulou C, Gangaplara A, Mallett G, Flomerfelt F, Liniany L, Knight D, et al. PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells. Immunity. 2018;49:247-263.e7 pubmed publisher

Nishimura Y, Gautam R, Chun T, Sadjadpour R, Foulds K, Shingai M, et al. Early antibody therapy can induce long-lasting immunity to SHIV. Nature. 2017;543:559-563 pubmed publisher

Locke F, Neelapu S, Bartlett N, Siddiqi T, Chavez J, Hosing C, et al. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Mol Ther. 2017;25:285-295 pubmed publisher